Acute Coronary Syndromes, Ticagrelor, Dyspnea
Conditions
Keywords
Nursing, Ticagrelor, Hand fan therapy, Dyspnea, Non-pharmacological intervention
Brief summary
This study will be conducted in the coronary intensive care unit of Dr. Siyami Ersek Chest, Heart and Vascular Surgery Training and Research Hospital. It aims to investigate the effect of hand fan therapy on ticagrelor-associated dyspnea in patients receiving ticagrelor.
Detailed description
Patients in the coronary intensive care unit receiving ticagrelor and meeting the inclusion criteria will be included. The study includes two groups: a control group receiving standard care and an experimental group receiving standard care plus hand fan therapy. A total of 110 participants (55 per group) will be recruited. Randomization will be performed using a computer-based randomization program. Due to the nature of the intervention and sample characteristics, participants and the researcher will not be blinded. Data will be analyzed by a statistician not involved in the study, and the findings will be reported.
Interventions
OTHERSTANDART CARE
Routine ward care including semi-Fowler position and breathing exercises. Standard institutional care will be applied. Presence, number, and severity of dyspnea attacks will be recorded during the first 2 hours after ticagrelor administration.
OTHERSTANDART CARE & FAN THERAPY
In addition to standard care, patients will undergo hand fanning for 5 minutes at 30, 60, and 120 minutes after ticagrelor administration. The fan will be directed toward the patient's face from a distance of \ 15 cm. Dyspnea severity and number of episodes will be recorded during this period.
Sponsors
Acibadem University
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
SINGLE (Outcomes Assessor)
Masking description
Outcomes will be assessed by a statistician not involved in the study. Participants and researchers will not be blinded due to the nature of the intervention.
Intervention model description
Participants will be randomized into two groups: control and experimental. Randomization will be computer-based. Data will be analyzed by a statistician not involved in the study.
Eligibility
Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
Yes
Inclusion criteria
* Between the ages of 18 and 65, * No severe hearing and vision problems, * Can speak and understand Turkish, * Easy to communicate with, * First-time sufferer of acute coronary syndrome (ACS) for the first time, * Decided to start ticagrelor therapy, * Able to adapt to treatment, * Individuals who volunteered to participate in the research.
Exclusion criteria
* Having any problem that prevents you from communicating cognitively, emotionally and verbally, * Obstructive sleep abnormalities, * Have a disease that affects respiratory function (stage IV cancer, bronchial asthma, COVID-19, lung cancer, pulmonary edema, chronic obstructive pulmonary disease, pulmonary hypertension, pulmonary embolism, pneumonia or bronchitis, etc.), * With metabolic abnormalities, * Intubated after the procedure, * Previously treated with ticagrelor, * Individuals who did not volunteer to participate in the study. Losses to follow up * Individuals who wish to leave the study voluntarily. * Saturation value below 95%, * The one with the arrest, * Who will not be able to fulfill the requirements of the work, * Individuals with life-threatening conditions
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Incidence of ticagrelor-associated dyspnea | Time Frame: 0-120 minutes after ticagrelor administration (T1: baseline; T2: 30 min; T3: 60 min; T4: 120 min) Unit of Measure: Percentage of participants (%) | The proportion of participants who experience dyspnea within 120 minutes following ticagrelor administration will be recorded. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Time to onset of ticagrelor-associated dyspnea | Time Frame: Within 120 minutes after ticagrelor administration (T1-T4) Unit of Measure: Minutes (min) | The time interval between ticagrelor administration and the first reported dyspnea episode will be measured in minutes. |
Other
| Measure | Time frame | Description |
|---|---|---|
| Severity of ticagrelor-associated dyspnea | Time Frame: 0-120 minutes after ticagrelor administration (T1: baseline; T2: 30 min; T3: 60 min; T4: 120 min) Unit of Measure: Score (0-10) | Dyspnea severity will be assessed using the Modified Borg Dyspnea Scale (0-10) at T1 (baseline), T2 (30 min), T3 (60 min), and T4 (120 min) after ticagrelor administration. Higher scores indicate greater symptom severity. |
Countries
Turkey (Türkiye)
Contacts
Primary ContactEmine Tuğba YORULMAZ, research assistant
Backup ContactArzu ERKOÇ, Associate professor
Outcome results
None listed